PMID- 33747214
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210323
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 21
IP  - 5
DP  - 2021 May
TI  - In vivo isolation of circulating tumor cells in patients with different stages of 
      prostate cancer.
PG  - 357
LID - 10.3892/ol.2021.12618 [doi]
LID - 357
AB  - Circulating tumor cells (CTCs) provide accurate information on the clinical stage 
      of cancer progression. The present study examined the clinical validity and 
      feasibility of a new medical device for the in vivo isolation of CTCs from the 
      blood of patients with prostate cancer (PCa). The GILUPI CellCollector((R)) (DC01) 
      was applied in 188 cases. The CTC/prostate-specific antigen (PSA) profile of each 
      patient was checked for therapeutic monitoring of patients with PCa. The 
      CellCollector, which is a unique in vivo approach for the isolation of CTCs, was 
      compared with the CellSearch((R)) system, which is the current standard. Overall 
      survival (OS) and diagnostic performance were evaluated. By in vivo isolation, 
      78.9% (56/71) of patients with metastatic disease (PCa-m) and 46.3% (24/53) of 
      patients with localized disease (PCa-l) had >/=1 captured CTC. Kaplan-Meier 
      analysis revealed that patients with PCa-m that had >/=5 CTCs had a significantly 
      different OS compared with those with <5 CTCs (27.5 months vs. 37 months; HR 2.6; 
      95% CI 0.78-8.3). Patients with a higher number of CTCs at all time-points had 
      the shortest median OS of 25 months (HR 1.9; 95% CI 0.4-11.6). The effectiveness 
      of CTC isolation technologies demonstrated that in 65.7% of the applications, 
      patients with cancer were positive for CTCs using the CellCollector. By contrast, 
      the CellSearch system detected CTCs in 44.4% of applications. In vivo isolation 
      of CTCs demonstrated the clinical viability of the CellCollector, related to the 
      current standard for the isolation of CTCs from patients with PCa. The advantage 
      of the in vivo device is that it overcomes the blood volume limitations of other 
      CTC assays. Furthermore, the present study revealed that the CellCollector was 
      well tolerated, and no adverse events (AEs) or serious AEs were reported.
CI  - Copyright: (c) Theil et al.
FAU - Theil, Gerit
AU  - Theil G
AD  - Medical Faculty of Martin Luther University Halle-Wittenberg, University Clinic 
      and Outpatient Clinic for Urology, D-06120 Halle (Saale), Germany.
FAU - Boehm, Catrin
AU  - Boehm C
AD  - Medical Faculty of Martin Luther University Halle-Wittenberg, University Clinic 
      and Outpatient Clinic for Urology, D-06120 Halle (Saale), Germany.
FAU - Fischer, Kersten
AU  - Fischer K
AD  - Medical Faculty of Martin Luther University Halle-Wittenberg, University Clinic 
      and Outpatient Clinic for Urology, D-06120 Halle (Saale), Germany.
FAU - Bialek, Joanna
AU  - Bialek J
AD  - Medical Faculty of Martin Luther University Halle-Wittenberg, University Clinic 
      and Outpatient Clinic for Urology, D-06120 Halle (Saale), Germany.
FAU - Hoda, Raschid
AU  - Hoda R
AD  - Medical Faculty of Martin Luther University Halle-Wittenberg, University Clinic 
      and Outpatient Clinic for Urology, D-06120 Halle (Saale), Germany.
FAU - Weber, Ekkehard
AU  - Weber E
AD  - Institute of Physiological Chemistry, Medical Faculty of Martin Luther University 
      Halle-Wittenberg, D-06120 Halle (Saale), Germany.
FAU - Schonburg, Sandra
AU  - Schonburg S
AD  - Medical Faculty of Martin Luther University Halle-Wittenberg, University Clinic 
      and Outpatient Clinic for Urology, D-06120 Halle (Saale), Germany.
FAU - Kawan, Felix
AU  - Kawan F
AD  - Medical Faculty of Martin Luther University Halle-Wittenberg, University Clinic 
      and Outpatient Clinic for Urology, D-06120 Halle (Saale), Germany.
FAU - Fornara, Paolo
AU  - Fornara P
AD  - Medical Faculty of Martin Luther University Halle-Wittenberg, University Clinic 
      and Outpatient Clinic for Urology, D-06120 Halle (Saale), Germany.
LA  - eng
PT  - Journal Article
DEP - 20210304
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC7967937
OTO - NOTNLM
OT  - CellCollector(R)
OT  - circulating tumor cells
OT  - in vivo isolation
OT  - liquid biopsy
OT  - prostate cancer
COIS- The authors declare that GILUPI GmbH supported the present study. We received 
      funding from GILUPI GmbH; they provided the CellCollector and the patients 
      received travel expenses. The sponsor played no role in the study. GILUPI GmbH 
      provided the schematic image of the wire (Fig. 1).
EDAT- 2021/03/23 06:00
MHDA- 2021/03/23 06:01
PMCR- 2021/03/04
CRDT- 2021/03/22 08:11
PHST- 2020/11/26 00:00 [received]
PHST- 2021/02/10 00:00 [accepted]
PHST- 2021/03/22 08:11 [entrez]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/03/23 06:01 [medline]
PHST- 2021/03/04 00:00 [pmc-release]
AID - OL-0-0-12618 [pii]
AID - 10.3892/ol.2021.12618 [doi]
PST - ppublish
SO  - Oncol Lett. 2021 May;21(5):357. doi: 10.3892/ol.2021.12618. Epub 2021 Mar 4.